News All News
Press Contact: Kirsten Mabry | (617) 495-4157
Tag: Sponsored Research
March 21st, 2016
Research alliance will advance small-molecule therapy for most common form of acute leukemia, targeting proteins involved in transcriptional regulation.
December 23rd, 2015
UCB-funded Harvard study describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.
July 21st, 2015
Biologists at Harvard Medical School, with support from Biogen, have mapped protein networks in the human 'interactome'.
April 1st, 2015
Paris (France), 1 April 2015 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it has signed a multi-year research alliance agreement with Harvard University in Cambridge, Mass.
July 15th, 2013
Paris (France), 15 July 2013 - Ipsen (Euronext: IPN, ADR: IPSEY) announced today that it
has initiated a research and development collaboration on novel engineered botulinum toxins
with Harvard Medical School (Harvard).
Under the terms of the agreement, Ipsen will fund Harvard research for at least three years
with the aim to discover, evaluate and develop novel engineered recombinant botulinum
toxins for the treatment of serious neurologic diseases.